Pendulum Therapeutics
Biotechnology • San Francisco, United States
Pendulum Therapeutics is the leading innovator in microbiome science, delivering research based probiotic formulations to support metabolic health. The company leverages cutting-edge research and strong intellectual property to bring effective, science-backed solutions to consumers worldwide. Pendulum Akkermansia was the first novel species to be brought to the probiotics market in more than 50 years. The first and only probiotic in the world clinically proven to lower A1C and blood glucose in people with type 2 diabetes, Akkermansia stimulates natural GLP-1 production.
Headcount
118
51-200 employees
Hiring
8
Open roles
Revenue Signal
$3M
Estimated annual revenue
Last Round
$0
Most recent funding amount
